Skip to main content
. Author manuscript; available in PMC: 2019 Jan 10.
Published in final edited form as: J Clin Immunol. 2014 Dec 13;35(2):112–118. doi: 10.1007/s10875-014-0116-2

Fig. 3. EBV-specific T-cell responses in XMEN patient compared with a healthy control and a patient with a hypomorphic mutation in XIAP resulting in the expression of a truncated protein.

Fig. 3

a CFSE proliferation assay of PBMCs using medium (nil), PHA, and EBV lysate. b OX-40 assay using medium (nil), PHA, VZV and EBV lysates. Cells are gated to acquire 30, 000 CD3+ events, a negative gate is applied to exclude monocytes and apoptotic cells that may aberrantly express activation markers, then dual expression of activation markers CD25 and CD134 (OX-40) is measured amongst the CD4+ population; the gate coordinates are fixed to give 0.1% double positive events in the nil tube (supplementary methods section)